Logo

AstraZeneca and Moderna Present Results of AZD8601 in P-IIa EPICCURE Trial for the Treatment of Heart Failure at AHA 2021

Share this
AstraZeneca and Moderna Present Results of AZD8601 in P-IIa EPICCURE Trial for the Treatment of Heart Failure at AHA 2021

AstraZeneca and Moderna Present Results of AZD8601 in P-IIa EPICCURE Trial for the Treatment of Heart Failure at AHA 2021

Shots:

  • The P-IIa EPICCURE trial evaluates safety, tolerability & exploratory efficacy of epicardial inj. of AZD8601 vs PBO in 11 patients (7 were treated with AZD8601 & 4 received PBO inj.) with stable CAD & decreased LVEF who undergoes CABG surgery. The therapy is being co-developed with Moderna
  • The study met its 1EPs i.e., numerical trends were identified in 3 exploratory efficacy EPs over PBO, including an increase in LVEF & functional PROs, 7 patients treated with AZD8601 had NT-proBNP
  • AZD8601 is a novel mRNA-based therapy that encodes for VEGF-A. AstraZeneca has signed an exclusive agreement with Moderna to discover & commercialize mRNA therapeutics for multiple diseases

  Ref: AstraZeneca | Image: Mint

Click here to­ read the full press release 

Tuba

Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions